Melioidosis, a tropical infection commonly manifesting as acute pneumonia and sepsis in humans, is caused by the Gram-negative Tier 1 select agent Burkholderia pseudomallei and represents a global public health threat with an estimated 165,000 cases and 89,000 deaths annually worldwide (an overall mortality rate of 54%). Unfortunately numerous barriers exist to decreasing the burden of melioidosis including lack of an effective vaccine, difficulty diagnosing and identifying high-risk patients, and challenges in treatment due to extensive antimicrobial resistance of B. pseudomallei and lack of targeted immunotherapies. While work to date spotlights the promise of the application of advanced technologies to melioidosis and identifies several targets for further study, an incomplete understanding of the pathogenic mechanisms underlying host susceptibility and outcome impedes efforts to prevent, diagnose, risk-stratify and treat this infection. The overall hypothesis of this project is that by generating and integrating a rich compendium of multidimensional data ? transcriptomic, proteomic, and metabolomic ? from circulating immune cells and blood of patients with melioidosis and selected controls, it is possible to identify fundamental biological pathways and processes activated during melioidosis. Such comprehensive data, complemented by targeted in vitro experiments, are desperately needed to inform the design of vaccines, diagnostics, prognostics and therapeutics to combat this infectious threat. This hypothesis will be tested in the following aims: 1) Identify biological pathways that distinguish melioidosis from other causes of sepsis; 2) Define biological processes and develop prognostic signatures that predict death in melioidosis; and 3) Validate the function of key genes and pathways in human cells infected with B. pseudomallei in vitro. This application leverages the investigators? scientific and clinical expertise in melioidosis, cutting edge bioinformatics capacity in transcriptomics, proteomics, and metabolomics both as independent domains and integrated together, and a rich clinical and biological dataset of over 5,000 septic patients due to melioidosis or to other infections. The successful completion of this project will yield an unprecedented granular overview of mechanisms leading to melioidosis and the molecular signatures associated with clinical outcomes, while also providing a unique resource to the scientific community to guide further research into this important but neglected disease.

Public Health Relevance

Melioidosis is an often severe bacterial infection that occurs in tropical regions around the world. The objective of this project is to leverage cutting edge technologies to identify specific biological pathways involved in the host's immune and inflammatory response to this infection. The knowledge gained from this proposal can help identify novel strategies for diagnosis, prognosis, vaccine development, and treatment of melioidosis, and ultimately improve public health in endemic regions.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
1R01AI137111-01
Application #
9495462
Study Section
Clinical Research and Field Studies of Infectious Diseases Study Section (CRFS)
Program Officer
Mukhopadhyay, Suman
Project Start
2018-08-23
Project End
2022-07-31
Budget Start
2018-08-23
Budget End
2019-07-31
Support Year
1
Fiscal Year
2018
Total Cost
Indirect Cost
Name
University of Washington
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
605799469
City
Seattle
State
WA
Country
United States
Zip Code
98195